title: Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy.
abstract: The treatment of deep fungal infection in haematological malignancy remains controversial due to the limited number of antifungal agents available and problems over their spectrum and dose-limiting side-effects. Difficulties in diagnosis mean that most treatments are begun empirically; amphotericin B remains the drug of choice. Emerging resistance may limit the usefulness of fluconazole and other azoles in some areas. Lipid preparations of amphotericin B have reduced the toxicity of this agent, but some issues of dosage and efficacy remain. Adjunctive treatments aimed at augmenting the host response to infection may have a role to play in deep fungal infection.
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D005437:Flucytosine / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B; D005437:Flucytosine